Member Info for NelsontheDog

Mikey,
Just ran your numbers as I presumed there must be a glitch - didnt find one. $5bn!!!!!
Holy Moly - I'm rich. richer than I ever thought - just cash poor at the moment....
This really is a giant giant business in the making.
Command and Control
NtD

Hopeful that PGM basket price will come back. Large imopact due to car chip shortages reducing cars produced. This will pass and there will be latent demand for cars. Then also hydrogen economy demand for PGM's to keep demand high hopefully.

Homey
Thats some rabbit-hole you are trying to drag this BB down in discussing "non-essential". We shouldnt go there, its non-essential.
AtB
NtD

Hi
With the new deals, has anyone got a view of the assets we now hold in terms of tonnage of tailings, their estimated metals content and thus its recoverable value? We are valued at circa £400m, what level of assets do we currently own?
Would be an interesting number to tout about imho and if anyone has already done some maths on this and happy to share I would be very grateful.
NtD

Its a highly complex world with shareholders having all sorts of targets, fears, demands, excitement and targets - I obviously sincerely wish good fortune to all.

And equally, the company is in the process of moving from minnow to major over the long term and there are many ways to get there with many macro and intra company risks and decisions to be taken.

I am happy with progress and happy with management. I like the process of expanding the interest in JV's - if we already are going to drive the progress I like to have as much skin in the game for the expectant returns. IMHO the scarcest resource for Jubilee is good management and managers so the more return per management time seems astute to me.

IMHO, this is a £2billion+ company disguised as an AIM minnow stock and I am thankful that I have the ability to patiently wait for the sheeps clothing to be removed by the market over the next few years. And it wont reveal a wolf, an elephant a Deer or a goat - nope its a multi-headed cash-spewing monster!!!

GLA
NtD

Foxy,

Wavering is okay, breaking isnt. Fundamentals and free cash flow are stellar so share price will eventually have to rise to reflect this. Not sure how that will reflect in the chart but pretty confident how it will reflect in my pocket!

Well spotted Supafix - we should be rising from here given the cash generation in play.

I really hope there is a legacy product deal soon. Suzy getting on with the new strategy and from comments from Rhubarb this is where Valirx may be brilliant. My only caution is what happens when you develop the new product - you have to sell it, you have to DO A DEAL! Otherwise you add no value and good drugs dont get to market.

In my short time as holder we have hads this before where we all anticipate the deal before the news event, but the event is to talk of the new strategy - an area where Suzy seems to be very enthusiastic.

The event will allow us a view on whether a deal will fund the new strategy (in which case why did we need Cenkos) or we will be raising capital for new drug roll-outs (with Cenkos help).

Not long till we find out.

GLA
NtD

Cane toad, I hope you are right. In addition to a broker note, we could get tipped by a share tip sheet - as well as the good fundamentals, it’s an interesting product (diamonds) and the most famous mine in the world for getting them - that all makes for a good tip write up imho

I think todays news explains the last few weeks lower price. I think that on placing we will again start to rise to a more suitable level for the promise of JLP.
I was beginnig to think that JLP might be the perfect share - but it just goes to show that there is never a perfect share - there will always be an annoyance. As with people, you get to choose whether you dwell on the annoyance or enjoy all the good stuff - I am going to go with the latter of which there is so much with this company.
GLA
NtD

*prima donna
*in clover

Mike
100% agree. I am amazed that following the disaster of accustem, the board is expending energy and prioritisation on another corporate initiative.

They are as awful at this side of business as they are exciting with the pharma side.

This latest change of listing strikes me as an example of GC or a Donna behaviour - it’s not him, it’s the U.K. shareholders holding this back.

If they put all focus in Foralumab and their other opportunities we would be akin clocer.

I would sell but I am hugely in red and excited by Foralumab.

Boris's winter plan;
bwah bwah bwah, i've put on my finest jumper from the isle of Arran and, ziggy ziggy mfoowalah, I have bought a splendid Balaclava on ebay....

oh, and NFT and media uses for blockchain rapidly expanding - further use case expansion

I am sure there will be a top but I am not so convinced that the phases will be as defined from here on out. BTC gaining more adoption should see faster dip responding, utility of ETH and ETH wannabe's means there is a use case. Interest on PoS means the yield curve will rise on crash's and income hunters will step in.
I know its still early but its nowhere near as early as it was in 2017 and as such I think its wrong to always look to history.
I see the PoS yield especially as a protection in KR1.
I know i am in the minority with this view but thought I would share and see if it resonates with anyone else.
NtD

Splendor
I saw that and have similar uncertainty. They have capex spend for Williamson despite this of 8-10m for this year. Have they spent the 8-10m already and following further review removed Williamson or is the 8-10m required to maintain a value (that we are not putting on our Balance sheet!!??)
I am a little unsure on this element but maybe the former has occurred - otherwise I cant make any sense of it.
NtD

Positive free cashflow of $120m with $62m of exceptional sales. So $58m positive fcf from normal activity.

With market improving towards on of 2021 FY that cash flow will get better.

Very happy with the results

Redwineday
Thanks for your post - very informative to me - i was not aware of the debt conditions. However we may still rerate on results as it will give a good indication of how long it will take to get to a net cash position and how much that journey would be reliant on large diamond sales.
Once we are net cash, we can use extra cash to return to shareholders or any other options and so the time to that event is key.

I do not expect us to rocket anytime soon, but I would hope that with an underlying positive cashflow excluding exceptional diamonds we may re-rate from the price to fail price to a more normal holding level - guessing that would be anywhere between 2p and the bond conversion price.

Therefore hoping for some upward acknowledgement of the journey to date here tomorrow.

NtD

Dartron
I installed the VOX market app on my phone - if you put your watchlist in, it will highlight RNS for those companies - finding this a much better methodology than Investegate / LSE RNS system.

I am viewing the lack of press as very good news.

I think they want to use press when they have the commercialisation locked down and gain joined publicity with whomever is going to be involved in the next leg. That is a much bigger press story - with a ready to go now message, and, if we have the right big hitters(i hope its Astazeneca) maybe even a MHRA emergency use to boot.

If the press release is its here now and ready to industrialise manufacture on Monday type message - thats a much bigger press (in fact a global headline) than a future hope. The fact they arent engaging the press yet to me implies that the commercial / mhra deal is very close - then we will get the fanfare etc. With the people involved I think SGS can pick up the phone to almost anyone to get this done and done to the best outcome.

Hence keeping tight hold of my shares for the moment and joining Twisty in the fairly relaxed camp.

GLA
NtD